We conducted a systematic review and meta-analysis of double-blind randomized controlled trials to quantify the dose-related systolic (SBP) and diastolic blood pressure (DBP) lowering efficacy of renin inhibitors vs placebo in the treatment of adults with primary hypertension. Databases searched were Medline (1966-March 2008, EMBASE (1988-March 2008 and Cochrane Central Register of Controlled Trials (CENTRAL). Six trials in 3694 patients met the inclusion criteria. All examined aliskiren, the only renin inhibitor licensed for marketing in Canada and the United States. Aliskiren caused a dose-related SBP/DBP lowering effect compared to placebo: weighted mean difference with 95% CI: aliskiren 75 mg, À2.9 (À4.6, À1.3)/À2.3 (À3.3, À1.3) mm Hg; aliskiren 150 mg, À5.5 (À6.5, À4.4)/À3.0 (À3.7, À2.3) mm Hg; aliskiren 300 mg, À8.7 (À9.7,À7.6)/À5.0 (À5.6, À4.3) and aliskiren 600 mg, À11.4 (À13.5, À9.2)/À6.6 (À7.9, À5.2) mm Hg. Aliskiren 300 mg significantly lowered both SBP À3.0 (À4.0, À2.0) and DBP À1.7 (À2.3, À1.0) as compared to aliskiren150 mg. Aliskiren has no effect on blood pressure variability. No data were available to assess the effect of aliskiren on heart rate or pulse pressure. This review found weak evidence that during 4-to 8-week use, aliskiren did not increase withdrawals due to adverse effects as compared to placebo. We concluded that aliskiren has a dose-related blood pressure lowering effect better than placebo and magnitude of effect is similar to that determined for angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
Introduction
Hypertension is a chronic condition associated with an increased risk of mortality and morbidity from stroke, coronary heart disease, congestive heart failure and renal disease. For patients with established hypertension, blood pressure (BP) should first be managed with lifestyle/behaviour modification. However, if these measures prove inadequate then pharmacotherapy is indicated. The reninangiotensin-aldosterone system (RAAS) is a major regulator of cardiovascular homeostasis. It is influenced by five distinct anti-hypertensive drug classes: b-adrenergic blockers, renin inhibitors, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs) and aldosterone inhibitors.
Attempts to block renin began in the 1950s with the use of renin antibodies. 1 Issues of potency, bioavailability and duration of action and cost of synthesis have marred the drug development. For example, potent renin inhibitors such as remikiren and enalkiren had low oral bioavailability. 2 Newer drugs such as zankiren and terlakiren looked more promising, but further development was halted in the mid-1990s with the development of ARBs. More recent programmes to develop renin inhibitors have been based on X-ray crystallography of renin's active site with computational modelling rather than based on the structure of angiotensinogen. 3 This has led to aliskiren, a new non-peptide, low-molecular-weight, orally active renin inhibitor, which has been approved in the United States, Canada and other countries for the treatment of hypertension.
This review was published in the Cochrane database of systematic reviews issue 4, 2008 .
Objectives
The primary objective is to quantify the dose-related systolic (SBP) and/or diastolic blood pressure (DBP) lowering efficacy of renin inhibitors vs placebo in the treatment of primary hypertension. Secondary objectives are to determine the effects of renin inhibitors on variability of BP, pulse pressure, heart rate, withdrawals due to adverse effects and rates of specific adverse effects such as dry cough and angiooedema. 
Methods

Search strategy
Criteria for considering studies for this review
Types of studies Study design had to meet the following criteria: double-blind, random allocation to a specific fixed dose of renin inhibitor or parallel placebo; duration of treatment of at least 3 weeks; BP measurements at baseline (following washout) and at one or more time points between 3 and 12 weeks after initiation of treatment.
Types of participants
Participants must have a baseline BP of at least 140 mm Hg SBP and/or a DBP of at least 90 mm Hg using a standard method of measurement, such as a calibrated standard mercury sphygmomanometer. Participants must not be restricted by age, sex, baseline risk or co-morbid conditions other than patients must not have creatinine levels greater than 1.5 times the normal level.
Types of interventions
Monotherapy should include different fixed doses of renin inhibitor. However, data from trials or arms of trials with variable doses, based on BP response, were not eligible.
Types of outcome measures
Primary outcomes: change from baseline of trough and/or peak SBP and DBP compared with placebo.
Secondary outcomes: change in standard deviation, pulse pressure, heart rate, number of patient withdrawals due to adverse effects and number of patients with dry cough or angio-oedema, compared to placebo.
Selection of trials
Two reviewers (VM and PF) independently screened the titles and the abstracts resulting from the search strategies. An article was rejected on initial screening if the title or abstract indicated that the article did not report data from a randomized placebocontrolled trial. Full texts of the remaining articles were retrieved. The bibliographies of pertinent articles, reviews and texts were searched for additional citations. Two independent reviewers assessed the eligibility of the trials using a trial selection form. Discrepancies were resolved by discussion, and when necessary by a third reviewer (JMW or KB).
Data extraction
Data were extracted independently by two reviewers VM and PF, and then cross-checked. All numeric calculations and graphic interpolations were confirmed by a second person.
Assessment of risk of bias in included studies
Two independent reviewers (VM and PF) assessed the risk of bias of all included trials and prepared a Risk of Bias Dealing with missing data In the case of missing values for standard deviation of the change in BP, the standard deviation was imputed based on the information in the same trial or from other trials using the same dose. The following hierarchy (listed from high to low preference) was used to impute standard deviation values: standard deviation of change in BP data from a different position (standing or supine); standard deviation of BP at the end of treatment; standard deviation of BP at baseline (except if this measure was used for entry criteria); mean standard deviation of change in BP from other trials using the same class of drug.
Assessment of heterogeneity
Test for heterogeneity of treatment effect between the trials used a w 2 -statistic. The fixed effects model was applied to obtain summary statistics of pooled trials, unless significant between-study heterogeneity was present, in which case the random effects model was used.
Data synthesis
Data synthesis and analyses used the Cochrane Review Manager software, RevMan 5.0. Data for changes from baseline in BP were combined using a weighted mean difference method. The withdrawals due to adverse effects were analysed using relative risk.
Subgroup analysis and investigation of heterogeneity
The following subgroup analyses were planned a priori-race: African-American, white and others; age: adults 18-69 years, more than 70 years old; baseline severity of hypertension: mild, moderate, severe. All trial participants had mild to moderate hypertension. When heterogeneity was significant, the factors contributing to heterogeneity were investigated.
Sensitivity analysis
We planned to test the robustness of the results using several sensitivity analyses: trials of high risk vs low risk of bias; trials that are drug manufacturer vs non-manufacturer sponsored; trials that assess drug as primary drug of investigation vs trials that assess drug as comparator; trials with BP data measured in the sitting vs other positions; trials with published standard deviations of BP change vs imputed standard deviations.
Results
Of the 250 articles identified in the search, six trials comparing the renin inhibitor, aliskiren (N ¼ 2452), to placebo (N ¼ 1242) met the inclusion criteria ( Figure 1 ). All included trials were randomized, double-blind and parallel group multi-centre studies of 8 weeks duration, except for Kushiro 2006, which was 13 weeks duration. 4 The manufacturer (Novartis) sponsored all six included randomized controlled trials. We contacted the manufacturer by email for any additional information on ongoing studies and for missing data on heart rate and pulse pressure from published trials meeting our inclusion criteria. No response was provided.
Following a 1-2-week washout period from any prior anti-hypertensive medications, all trials had a 2-to 4-week single-blind placebo-controlled run-in period, followed by 8 weeks of randomized treatment. All trials had similar inclusion and exclusion criteria. Patients were at least 18 years of age with mild to moderate essential hypertension defined as mean sitting diastolic blood pressure (MSDBP) equal to 95 mm Hg and less than 110 mm Hg at baseline. One trial Kushiro 2006 was conducted in Japanese patients between the ages 20 and 80 years. 4 Patients were excluded if pregnant or breast feeding; had MSDBP equal to or greater than 110 mm Hg and/or mean sitting systolic blood pressure (MSSBP) equal to or greater than 180 mm Hg; had a history or evidence of secondary hypertension, type I or type II diabetes with poor glycaemic control or any surgical or medical condition that might alter the absorption, distribution, metabolism or excretion of study drugs. Patients were also excluded if they had a history of severe cardiovascular, cerebrovascular, hepatic or renal disease.
When BP measurement data were available in more than one position, data were extracted in accordance with the following order of preference: (1) sitting, (2) standing and (3) supine. In all trials, MSSBP and MSDBP were available for baseline measurements, and least-squares mean (LSM) change from baseline and standard error (s.e.) of the change were available at regular intervals throughout trials (usually at weeks 1, 2, 4, 6 and 8). If BP measurements were available at more than one time during a 24-h period, the trough measurement was used. Peak level is defined as within 12 h of the drug ingestion and trough level is defined as between 12 and 24 h. The sitting clinic BP was measured using a 
or an alternative calibrated method, in accordance with the 1988 AHA Committee Report on Blood Pressure Determination. Blood pressure was measured at trough (24±3 h after dose). At the first study visit, the patient's arm with the highest sitting DBP became the arm used for all subsequent readings in the study. At each study visit, BP was measured three times at 1-to 2-min intervals, with the mean of the three measurements used as the BP for that visit. In addition, one BP measurement was taken in standing position after the patient stood for 2 min.
The mean age of patients across all trials ranged from 51 to 57 years, the majority were Caucasians (58-95%), except in Kushiro et al. trial (Japanese patients); the mean baseline SBP ranged from 151 to 155.6 mm Hg and DBP ranged from 99 to 100. 4 6, 7 In the Villamil 2007 trial, the MSDBP standard deviation for the placebo arm was imputed from the value of the s.e. given for aliskiren. 6 Further, there were no s.e. values for MSSBP for placebo and aliskiren 75, 150 and 300 mg. These were imputed from the average of the s.e. values given for combination therapies. In the Oparil 2007 trial, MSDBP and MSSBP standard deviations for both the placebo and aliskiren 300 mg groups were imputed from the values for s.e. given at week 4 for placebo and aliskiren 150 mg, respectively. 7 Because significant heterogeneity was present when meta-analysing MSSBP and MSDBP for aliskiren 150 and 300 mg as compared to placebo, the random effects model was used. Heterogeneity could not be explained based on the inclusion/ exclusion criteria and baseline characteristics because they were similar in all trials. It could be partly explained by the large placebo response observed in the Pool 2007 trial (SBP, À10.0 mm Hg; DBP, À8.6 mm Hg) as compared to placebo response in the other four trials. When this trial was removed from the analysis, heterogeneity was no longer significant. 5 
Sensitivity analysis
No sensitivity analyses occurred because all trials were sponsored by the manufacturer; used aliskiren as the primary drug of investigation; measured BP in sitting position as opposed to only standing or supine position. There was no significant difference observed in the effect size of both SBP and DBP using random effects model when sensitivity analyses were conducted using standard deviation values of trials reporting them vs imputing standard deviation values based on information from other trials. were free of selective reporting, and it was unclear whether any trial was free of other bias. 4, 7, 9 Overall the included trials were of high quality.
Risk of bias in included studies
Effects of interventions
Mean change from baseline of trough SBP compared with placebo Aliskiren monotherapy was superior to placebo in lowering MSSBP. The additional magnitude of BP lowering minus the placebo effect: aliskiren 75 mg vs placebo À2.94 (95% CI À4.56, À1.31); aliskiren 150 mg vs placebo À5.45 (95% CI À6.46, À4.43); aliskiren 300 mg vs placebo À8.66 (95% CI À9.68, À7.64); aliskiren 600 mg vs placebo À11.36 (95% CI À13.53, À9.19) (Figure 2 ).
Mean change from baseline of trough DBP compared with placebo Aliskiren monotherapy was superior to placebo in lowering MSDBP. The additional magnitude of BP lowering minus the placebo effect: aliskiren 75 mg vs placebo À2.29 (95% CI À3.31, À1.26); aliskiren 150 mg vs placebo À3.00 (95% CI À3.65, À2.34); aliskiren 300 mg vs placebo À4.97 (95% CI À5.62, À4.31); aliskiren 600 mg vs placebo À6.57 (95% CI À7.92, À5.23) (Figure 3 ).
Change in standard deviation compared with placebo
End of treatment standard deviation of SBP and DBP was similar in the placebo and aliskiren arms. Standard deviation of SBP ranged from 12.4 to 14.0 in the aliskiren treatment arm as compared to 12.0 to 14.0 in the placebo treatment arm. Standard deviation of DBP ranged from 8.0 to 8.6 in both the aliskiren and placebo treatment arms. This is consistent with aliskiren having no effect on BP variability.
Change in pulse pressure compared with placebo No trials reported on pulse pressure at baseline or end point.
Change in heart rate compared with placebo Two trials recorded baseline heart rate, but no data were provided at week 8.
5,8
Number of patient withdrawals due to adverse events compared with placebo There were no significant differences in withdrawals between placebo and aliskiren at any dose. RR with 95% CI for aliskiren 75 mg vs placebo was 0.97 (0.49, 1.89); for aliskiren 150 mg vs placebo was 1.01 (0.61, 1.69); for aliskiren 300 mg vs placebo was 0.91 (0.57, 1.47) and for aliskiren 600 mg vs placebo was 0.63 (0.21, 1.89).
Number of patients with dry cough or angio-oedema as compared to placebo One trial Pool 2007 reported on incidence of dry cough: placebo, n ¼ 2 (1.1%); aliskiren 75 mg, n ¼ 2 (1.1%); aliskiren 150 mg, n ¼ 5 (2.8%); aliskiren 300 mg, n ¼ 1 (0.6%). No trials reported angiooedema.
Mean change from baseline of trough systolic as well as diastolic blood pressure comparing different doses of aliskiren The BP lowering efficacy of aliskiren 150 vs 75 mg as well as aliskiren 600 vs 300 mg was not significantly different. However, aliskiren 300 mg significantly lowered both systolic and diastolic as compared to 150 mg (SBP with 95% CI: À2.97 (À3.99, À1.95) and DBP: À1.66 (À2.32, À1.0)) (Figures 4 and 5) .
Discussion
The RAAS is a major regulator of cardiovascular homeostasis, in which the vasoactive peptide, Figure 2 Dose ranging systolic blood pressure lowering effect of aliskiren vs placebo. Systolic blood pressure was significantly reduced by aliskiren 75 mg to 600 mg dose as compared to placebo, a mean reduction ranging from 2.9 to 11.4 mm Hg.
angiotensin II, has an important function. Renin inhibitors prevent the formation of renin, the enzyme that catalyses the conversion of angiotensinogen to angiotensin I, the rate-limiting step in this cascade. Renin is responsible for all 'downstream' events leading to production of angiotensin II and Figure 3 Dose ranging diastolic blood pressure lowering effect of aliskiren vs placebo. Diastolic blood pressure was significantly reduced by aliskiren 75 mg to 600 mg dose as compared to placebo, a mean reduction ranging from 2.3 to 6.6 mm Hg. Figure 4 Systolic blood pressure lowering effect of aliskiren 300 vs 150 mg. Systolic blood pressure was significantly reduced by aliskiren 300 mg as compared to 150 mg, a mean reduction of 3.0 mm Hg.
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VM Musini et al subsequent stimulation of its receptors. Because renin is the only enzyme that catalyses this conversion, it has been speculated that renin inhibitors might provide a more effective means of blockade of the RAAS than is possible with ACE inhibitors or ARBs. 10 ACE inhibitors and ARBs block this system further downstream by inhibiting the generation and action of angiotensin II, respectively. However, they do not block the RAAS completely.
The longest randomized controlled trial of renin inhibitors, Kushiro 2006 , is of 13 weeks duration. No trials have examined mortality or serious morbidity of aliskiren as compared to placebo.
To the best of our knowledge, this is the only systematic review summarizing the dose-related BP lowering efficacy of the renin inhibitors. Aliskiren is the only renin inhibitor that has been studied in double-blind randomized controlled trials to date and meet the minimum inclusion criteria of this review.
Dose-related efficacy
Aliskiren at all doses significantly lowered both SBP and DBP as compared to placebo. Of all aliskiren doses studied in the six included trials, aliskiren 300 mg showed the maximum BP lowering efficacy. SBP and DBP lowering with aliskiren 300 mg vs placebo was significantly greater than with aliskiren 150 mg. The magnitude of the BP lowering with aliskiren at the maximum recommended dose of 300 mg daily À8.7/À5.0 mm Hg is similar to ACE inhibitors À8/À5 mm Hg and ARBs À8/À5 mm Hg. [11] [12] [13] Direct comparison from the three placebo-controlled trials included in this systematic review that compared aliskiren 150 mg, aliskiren 300 mg with ARBs also supports this finding. Aliskiren 150 mg vs irbesartan 150 mg (SBP, À6.0 vs À7.2 mm Hg and DBP, À2.9 vs À2.5 mm Hg) and comparing aliskiren 300 mg to valsartan 320 mg (SBP, À5.1 to À13.0 vs À6.5 to À12.8; and DBP, À3.7 to À9.0 vs À2.7 to À9.7 mm Hg). This suggests that inhibiting the reninangiotensin system at different sites does not lead to clinically different BP lowering effects.
Adverse events
The included trials did not detect differences in adverse events between aliskiren and placebo. Some trial reports listed only a few events, generally those with an incidence greater than 1-2.5% in any group, while others reported by broad system affected by the drugs: cardiac, immune system, respiratory and so on. The most common adverse events reported were headache, nasopharyngitis, diarrhoea and back pain, which were similar in placebo groups and aliskiren groups at all doses. There was no distinction between total adverse events and serious adverse events, with only one trial Oparil 2007 reporting 'any serious adverse event'. 9 Two trials Pool 2007 and Kushiro 2006 reported on death with one death in the aliskiren 150 mg group 4 and another in the placebo group. 5 Limitations of this systematic review The intervention effect size as reported above and shown in Forrest plots could be an overestimate due to publication bias since the manufacturer sponsored all six published studies. It is likely that negative studies have not been published and therefore not included in this meta-analysis. In addition, the BP lowering efficacy estimate is limited to 8-13 weeks. It was not possible to do any subgroup analyses due to lack of data specific to race or age. Also the BP data at end point using the LSM is non-robust to data outliers, particularly if outliers have a skewed distribution. This can cause an increase in type 2 errors, and it is not known if there were significant outliers in the data.
Conclusions
Implications for practice The renin inhibitor aliskiren (150 and 300 mg) significantly lowered SBP and DBP as compared to placebo in a dose-dependent manner (SBP with 95% CI-150 mg: À5.5 (À6.5, À4.4); 300 mg: À8.7 (À9.7, À7.6) and DBP with 95% CI-150 mg: À3.0 (À3.7, À2.3); 300 mg: À5.0 (À5.6, À4.3)). This systematic Figure 5 Diastolic blood pressure lowering effect of aliskiren 300 vs 150 mg. Diastolic blood pressure was significantly reduced by aliskiren 300 mg as compared to 150 mg, a mean reduction of 1.7 mm Hg. review documents that aliskiren reduces BP by a magnitude that is similar to what has been determined with ACE inhibitors and ARBs. This review found weak evidence that in trials of 8 weeks duration aliskiren at any dose does not increase withdrawals due to adverse events as compared to placebo.
Implications for research
There is no evidence from randomized control trials that renin inhibitors reduce mortality or serious morbidity as compared to placebo or other classes of anti-hypertensive drugs. The BP lowering efficacy of renin inhibitors vs placebo or other classes of antihypertensive drugs is not known beyond 8 weeks. All published randomized controlled trials must provide data on all outcomes and all negative trials need to be published, for this review to be an accurate summary of the best available evidence.
